An Information Portal to 111749 Biological Macromolecular Structures

FLP is found in 10 entries
  •   Chemical Component Summary   Hide
    Identifiers (2S)-2-(2-fluorobiphenyl-4-yl)propanoic acid
    (2S)-2-(3-fluoro-4-phenyl-phenyl)propanoic acid
    Formula C15 H13 F O2
    Molecular Weight 244.26 g/mol
    Type non-polymer
    Isomeric SMILES
  •   Drug Info: DrugBank Hide
    DrugBank ID DB00712   (Different stereochemistry)
    Name Flurbiprofen
    • approved
    • investigational
    Description Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis. Flurbiprofen is structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen.
    • (+-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid
    • 2-(2-Fluorobiphenyl-4-yl)propanoic acid
    • 2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid
    • 3-Fluoro-4-phenylhydratropic acid
    • Ansaid
    • FLP
    • Flurbiprofen
    • Flurbiprofene
    • Flurbiprofeno
    • Flurbiprofenum
    • S-flurbiprofen
    Salts Flurbiprofen Sodium
    Brand names
    • Flurbiprofen
    • Flurbiprofen Sodium
    • Ocufen
    Affected organism Humans and other mammals
    Indication Flurbiprofen tablets are indicated for the acute or long-term symptomatic treatment of rheumatoid arthritis, osteorarthritis and anklosing spondylitis. It may also be used to treat pain associated with dysmenorrhea and mild to moderate pain accompanied by inflammation (e.g. bursitis, tendonitis, soft tissue trauma). Topical ophthalmic formulations may be used pre-operatively to prevent intraoperative miosis.
    Pharmacology Flurbiprofen, a nonsteroidal anti-inflammatory agent (NSAIA) of the propionic acid class, is structually and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen, and has similar pharmacological actions to other prototypica NSAIAs. Flurbiprofen exhibits antiinflammatory, analgesic, and antipyretic activities. The commercially available flurbiprofen is a racemic mixture of (+)S- and (-) R-enantiomers. The S-enantiomer appears to possess most of the anti-inflammatory, while both enantiomers may possess analgesic activity.
    Mechanism of action Similar to other NSAIAs, the anti-inflammatory effect of flurbiprofen occurs via reversible inhibition of cyclooxygenase (COX), the enzyme responsible for the conversion of arachidonic acid to prostaglandin G2 (PGG2) and PGG2 to prostaglandin H2 (PGH2) in the prostaglandin synthesis pathway. This effectively decreases the concentration of prostaglandins involved in inflammation, pain, swelling and fever. Flurbiprofen is a non-selective COX inhibitor and inhibits the activity of both COX-1 and -2. It is also one of the most potent NSAIAs in terms of prostaglandin inhibitory activity.
    Route of administration
    • ophthalmic
    • oral
    • Anti-Inflammatory Agents, Non-Steroidal
    • Cyclooxygenase Inhibitors
    • Analgesics
    • M01AE09
    • M02AA19
    • R02AX01
    • S01BC04
    • 28:08.04.92
    • 52:08.20
    CAS number 5104-49-4
    Name Sequence search Pharmacological action Actions
    Prostaglandin G/H synthase 1   Search  unknown inhibitor
    Prostaglandin G/H synthase 2   Search  yes inhibitor
Ligand Image